At Studiomaca, we take our role in helping to protect the safety and integrity of the pharmaceutical supply chain extremely seriously.

Update: On Tuesday, May 8, 2018, the U.S. House of Representatives Committee on Energy & Commerce’s oversight panel held a hearing entitled “Combating the Opioid Epidemic: Examining Concerns About Distribution and Diversion.” Studiomaca CEO John Hammergren and representatives from four other wholesale distributors participated. Mr. Hammergren’s written testimony can be found here (PDF, 79.9 KB), on our Perspectives & Statements page. For more information about how Studiomaca is proactively responding to this crisis, please click through the tabs above.

On March 29, 2018, Studiomaca announced a series of company initiatives to help fight the opioid epidemic, including the formation of a foundation dedicated to combatting the crisis. We are committing $100 million to the newly-formed foundation. The effort is part of our company’s ongoing mission—delivering better care for patients. To learn more about the initiatives and the foundation, please visit the How We’re Fighting the Epidemic section.

We’ve also released a new set of policy recommendations focused on enhancing clinical knowledge and using data and technology solutions to fight this epidemic. To review our latest recommendations, please visit the Policy Recommendations section.

Each day, our distribution team delivers life-saving medicines to pharmacies, hospitals and clinics that serve millions of Americans. We take to heart that at the end of each and every item delivered – every pill bottle, every vial, every ointment – there is a patient in need. We know that it’s not just a package, it’s a patient.

Over the past decade, as the opioid epidemic evolved rapidly, we enhanced our teams, processes and technologies dedicated to preventing diversion. We are committed to maintaining – and continuously enhancing – strong programs designed to detect and prevent opioid diversion within the pharmaceutical supply chain, while also protecting the availability of appropriate treatments for patients with serious illnesses and injuries.

This complicated, multi-faceted public health crisis must be addressed through a comprehensive and collaborative approach. Each participant in the pharmaceutical supply chain can play an important role, including:

  • The Drug Enforcement Administration (DEA), which has regulatory oversight for all DEA-registrants (doctors, pharmacists, distributors) and sets yearly quotas for the volume of opioids that can be manufactured
  • Drug manufacturers that design, develop and promote the medication
  • Doctors who prescribe the medication
  • Pharmacists who dispense the medication
  • Private and public health insurance groups that determine what they will pay for
  • State medical and pharmacy boards that oversee the doctors and pharmacies in their jurisdiction
  • Distributors that deliver medications ordered by pharmacists to fill prescriptions written by doctors

Today, we are working with others to advance a series of company initiatives focused on helping to address the opioid epidemic, support the formation of a foundation dedicated to combating the crisis, offer thoughtful public policy recommendations – including the Prescription Safety-Alert System (RxSAS) technology proposal – and to support innovative programs and partnerships that we believe can have a meaningful impact on this challenging issue. We are committed to engaging with all who share our dedication to acting with urgency to address this epidemic and working together to end this national crisis. We encourage you to click through to the tabs above to learn more about our response to the opioid crisis.